Biomaterial-based solutions find various applications in the healthcare system, e.g. in advanced therapy medicinal products or medical devices. However, the currently available methodologies are not sufficient for a proper risk assessment of all biomaterial applications. A new generalized testing system is necessary in order to standadise the evaluation of biomaterials.
The PANBioRA consortium will provide a more intelligent way of selecting the most suitable biomaterial for potential implants. Thus, possible post-implantation complications will be mitigated and reduced.
Objectives
The main objective of PANBioRA is to develop a method that allows the cost- and time effective assessment of
- a new biomaterial under healthy or disease state conditions (generalised testing) or
- a given biomaterial for a specific patient (personalised testing)
To achieve this goal, the PANBioRA consortium aims to develop a modular system using cross-disciplinary
techniques that will predict the patient-specific response to a given biomaterial. The testing system will integrate different technologies (refined, miniaturised versions of existing methods and new evaluation technologies) into a single instrument that will be able to perform multiple analyses on cell and micro-tissue levels.
With its multidisciplinary protocols and procedures, the PANBioRA testing system will set a new standard for the evaluation of biomaterials.